Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Long-Term Debt Repayments (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Long-Term Debt Repayments data on record, last reported at $1.4 million in Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments fell 99.41% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $5.4 million, down 97.68%, while the annual FY2025 figure was $5.4 million, 97.68% down from the prior year.
  • Long-Term Debt Repayments reached $1.4 million in Q4 2025 per MRVI's latest filing, roughly flat from $1.4 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $230.3 million in Q4 2024 and bottomed at $1.4 million in Q2 2022.
  • Average Long-Term Debt Repayments over 5 years is $13.3 million, with a median of $1.4 million recorded in 2022.
  • Peak YoY movement for Long-Term Debt Repayments: tumbled 99.64% in 2021, then surged 16834.78% in 2024.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $1.5 million in 2021, then fell by 9.33% to $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then soared by 16834.78% to $230.3 million in 2024, then tumbled by 99.41% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $1.4 million in Q4 2025, $1.4 million in Q3 2025, and $1.4 million in Q2 2025.